Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item TypeName
Academic Article Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Academic Article Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Academic Article Treatment advances in multiple myeloma.
Academic Article Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Academic Article Con: allogeneic transplantation in multiple myeloma.
Academic Article High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Academic Article Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.
Academic Article Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.
Academic Article Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
Academic Article Allografting or autografting for myeloma.
Academic Article Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
Academic Article Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Academic Article A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
Academic Article Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.
Academic Article Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Academic Article First thalidomide clinical trial in multiple myeloma: a decade.
Academic Article Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Academic Article High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Academic Article F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
Concept Survival Rate
Academic Article Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
Academic Article The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.
Academic Article Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Academic Article Long-term outcomes after autologous stem cell transplantation for multiple myeloma.
Academic Article BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.

Search Criteria
  • Survival Rate